Podchaser Logo
Home
Emerging Therapeutics in ADH1: Progress in Precision Medicine

Emerging Therapeutics in ADH1: Progress in Precision Medicine

Released Friday, 22nd March 2024
Good episode? Give it some love!
Emerging Therapeutics in ADH1: Progress in Precision Medicine

Emerging Therapeutics in ADH1: Progress in Precision Medicine

Emerging Therapeutics in ADH1: Progress in Precision Medicine

Emerging Therapeutics in ADH1: Progress in Precision Medicine

Friday, 22nd March 2024
Good episode? Give it some love!
Rate Episode

Host: Michael A. Levine, MD, FAAP, MACE, FACP

Host: B. Michelle Schweiger, DO, MPH

Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.

Show More

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features